Mpox Vaccine Maker Bavarian Nordic Ready to Produce 10 Million Doses by 2025

Danish pharmaceutical company Bavarian Nordic announced that it is prepared to produce up to 10 million doses of its mpox vaccine by 2025, following the World Health Organization’s (WHO) declaration of a global public health emergency due to the surge in mpox cases in Africa.

Rolf Sass Sorensen, vice-president of Bavarian Nordic, stated that the company has the capacity to manufacture an additional two million doses in 2024 and reach a total of 10 million doses by 2025. However, production will begin once the company receives confirmed orders from the affected countries.

Bavarian Nordic currently has approximately 500,000 doses in stock. The company’s mpox vaccine, known as Jynneos in the United States and Imvanex in the European Union, has been licensed since 2019. The recent WHO emergency declaration has led to a significant increase in Bavarian Nordic’s stock value on the Copenhagen Stock Exchange.

In response to the crisis, the Africa Centres for Disease Control and Prevention, in partnership with the European Union and Bavarian Nordic, has announced the deployment of over 200,000 vaccine doses across Africa. Since January 2022, there have been 38,465 reported cases of mpox in 16 African countries, resulting in 1,456 deaths.